Considerations on Immunization and Immunosuppression of Patients With Autoimmune Blistering Diseases During COVID-19 Pandemic in Brazil: Case Report

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2022 May 2

PMID 35495200

Authors

Denise Miyamoto

Claudia Giuli Santi

Celina Wakisaka Maruta

Valeria Aoki

Affiliations

Soon will be listed here.

Abstract

Autoimmune blistering diseases comprise a rare group of potentially life-threatening dermatoses. Management of autoimmune disorders poses a challenge in terms of achieving disease control and preventing adverse events. Treatment often requires an individualized approach considering disease severity, age, comorbidities, and infectious risk especially in the context of the ongoing COVID-19 pandemic. Knowledge regarding SARS-CoV-2 infection is still evolving and no specific antiviral therapy is available yet. We report four patients with active disease that required adjustment of treatment during the pandemic to discuss the use of immunosuppressants and immunobiologics, weighing potential risks and benefits of each therapy modality and vaccination status.

References

Cugno M, Marzano A, Bucciarelli P, Balice Y, Cianchini G, Quaglino P . Increased risk of venous thromboembolism in patients with bullous pemphigoid. The INVENTEP (INcidence of VENous ThromboEmbolism in bullous Pemphigoid) study. Thromb Haemost. 2015; 115(1):193-9. DOI: 10.1160/TH15-04-0309. View

Mahmoudi H, Salehi Farid A, Nili A, Dayani D, Tavakolpour S, Soori T . Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: A retrospective cohort study. J Am Acad Dermatol. 2020; 84(4):1098-1100. PMC: 7836213. DOI: 10.1016/j.jaad.2020.12.043. View

Cozzani E, Gasparini G, Sticchi L, Russo R, Icardi G, Parodi A . Considerations on SARS-Cov-2 vaccines in patients with autoimmune blistering diseases. Eur J Dermatol. 2021; 31(3):415-417. PMC: 8354837. DOI: 10.1684/ejd.2021.4043. View

Damiani G, Pacifico A, Pelloni F, Iorizzo M . The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?. J Eur Acad Dermatol Venereol. 2021; 35(10):e645-e647. PMC: 8447358. DOI: 10.1111/jdv.17472. View

Hwang E, Tomayko M . COVID-19 outcomes in patients with autoimmune blistering disease. Br J Dermatol. 2021; 185(5):1048-1050. PMC: 8239772. DOI: 10.1111/bjd.20571. View

Murrell D, Pena S, Joly P, Marinovic B, Hashimoto T, Diaz L . Diagnosis and management of pemphigus: Recommendations of an international panel of experts. J Am Acad Dermatol. 2018; 82(3):575-585.e1. PMC: 7313440. DOI: 10.1016/j.jaad.2018.02.021. View

Hanan N, Doud Jr R, Park I, Jones H, Mathew S . The Many Faces of Innate Immunity in SARS-CoV-2 Infection. Vaccines (Basel). 2021; 9(6). PMC: 8228170. DOI: 10.3390/vaccines9060596. View

Lorenz C, Ferreira P, Masuda E, Lucas P, Gardini Sanches Palasio R, Nielsen L . COVID-19 in the state of São Paulo: the evolution of a pandemic. Rev Bras Epidemiol. 2021; 24:e210040. DOI: 10.1590/1980-549720210040. View

Dong E, Du H, Gardner L . An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020; 20(5):533-534. PMC: 7159018. DOI: 10.1016/S1473-3099(20)30120-1. View

10.

Gambichler T, Hamdani N, Budde H, Sieme M, Skrygan M, Scholl L . Bullous pemphigoid after SARS-CoV-2 vaccination: spike-protein-directed immunofluorescence confocal microscopy and T-cell-receptor studies. Br J Dermatol. 2021; 186(4):728-731. PMC: 8653321. DOI: 10.1111/bjd.20890. View

11.

Sun Q, McMahon D, Ugwu-Dike P, Sun Q, Tang K, Zhang H . How Coronavirus Disease 2019 Changed Dermatology Practice in 1 Year Around the World: Perspectives from 11 Countries. Dermatol Clin. 2021; 39(4):639-651. PMC: 8452267. DOI: 10.1016/j.det.2021.05.014. View

12.

Vijenthira A, Gong I, Betschel S, Cheung M, Hicks L . Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients. Blood Adv. 2021; 5(12):2624-2643. PMC: 8216656. DOI: 10.1182/bloodadvances.2021004629. View

13.

Sokumbi O, El-Azhary R, Langman L . Therapeutic dose monitoring of mycophenolate mofetil in dermatologic diseases. J Am Acad Dermatol. 2012; 68(1):36-40. DOI: 10.1016/j.jaad.2012.07.003. View

14.

Strangfeld A, Schafer M, Gianfrancesco M, Lawson-Tovey S, Liew J, Ljung L . Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021; 80(7):930-942. PMC: 7843211. DOI: 10.1136/annrheumdis-2020-219498. View

15.

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

16.

Anuragi R, Kansal N . Immunobullous diseases, prothrombotic state, and COVID-19: Role of prophylactic anticoagulation in bullous pemphigoid and pemphigus. Dermatol Ther. 2020; 33(6):e14361. DOI: 10.1111/dth.14361. View

17.

Kridin K, Kridin M, Amber K, Shalom G, Comaneshter D, Batat E . The Risk of Pulmonary Embolism in Patients With Pemphigus: A Population-Based Large-Scale Longitudinal Study. Front Immunol. 2019; 10:1559. PMC: 6668600. DOI: 10.3389/fimmu.2019.01559. View

18.

Kridin K, Schwartz N, Cohen A, Zelber-Sagi S . Mortality in bullous pemphigoid: A systematic review and meta-analysis of standardized mortality ratios. J Dermatol. 2018; 45(9):1094-1100. DOI: 10.1111/1346-8138.14503. View

19.

Avancini J, Miyamoto D, Arnone M, Gabbi T, Ferreira P, Festa-Neto C . Absence of specific cutaneous manifestations of severe acute respiratory syndrome coronavirus 2 in a reference center in Brazil. J Am Acad Dermatol. 2020; 84(1):e67. PMC: 7491481. DOI: 10.1016/j.jaad.2020.09.030. View

20.

Kasperkiewicz M, Schmidt E, Amagai M, Fairley J, Joly P, Murrell D . Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic. J Eur Acad Dermatol Venereol. 2021; 35(7):e412-e414. PMC: 8013840. DOI: 10.1111/jdv.17207. View